Pediatric Hematology Providers' Contraceptive Practices for Female Adolescents and Young Adults with Sickle Cell Disease: A National Survey

Overview

Journal Pediatr Blood Cancer

Specialties Hematology
Oncology
Pediatrics

Date 2022 Jul 20

PMID 35856776

Authors

Megan A Askew

Arlene M Smaldone

Melanie A Gold

Kim Smith-Whitley

John J Strouse

Zhezhen Jin

Nancy S Green

Affiliations

Soon will be listed here.

Abstract

Background: Adolescent and young adult (AYA) women with sickle cell disease (SCD) have increased pregnancy-related health risks and are prescribed potentially teratogenic medications, yet limited data are available regarding pediatric SCD provider contraceptive practices. We aimed to assess pediatric hematology providers' beliefs, practices, motivators, and barriers for providing contraceptive care to female AYAs with SCD.

Methods: Guided by the Health Belief Model (HBM), we developed a 25-question, web-based survey to assess practices. Survey links were distributed nationwide to pediatric SCD and/or general hematology providers through their publicly available emails and by request to directors of U.S.-accredited Pediatric Hematology-Oncology fellowship programs for distribution to their SCD providers. Data analysis included descriptive statistics, chi-square analysis, and logistic regression.

Results: Of 177 respondents, 160 surveys meeting inclusion criteria were analyzed. Most providers reported counseling (77.5%) and referring female AYA patients for contraception (90.8%), but fewer reported prescribing contraception (41.8%). Proportionally fewer trainees provided counseling compared with established providers (54% vs. 85%, p < .001), with a similar trend for prescribing (p = .05). Prescription practices did not differ significantly by provider beliefs regarding potential teratogenicity of hydroxyurea. Key motivators included patient request and disclosure of sexual activity. Key barriers included inadequate provider training, limited visit time, and perceived patient/parent interest.

Conclusion: Provider contraceptive practices for female AYAs with SCD varied, especially by provider status. Health beliefs regarding teratogenic potential of hydroxyurea did not correlate with contraceptive practices. Clinical guidelines, provider training, and patient/parent decision-making tools may be tested to assess whether provider contraceptive practices could be improved.

References

Carmine L . Contraception for Adolescents with Medically Complex Conditions. Curr Probl Pediatr Adolesc Health Care. 2018; 48(12):345-357. DOI: 10.1016/j.cppeds.2018.11.004. View

Ferguson S, Trupin L, Yazdany J, Yelin E, Barton J, Katz P . Who receives contraception counseling when starting new lupus medications? The potential roles of race, ethnicity, disease activity, and quality of communication. Lupus. 2015; 25(1):12-7. PMC: 4679523. DOI: 10.1177/0961203315596079. View

Smith-Whitley K . Complications in pregnant women with sickle cell disease. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):359-366. PMC: 6913482. DOI: 10.1182/hematology.2019000039. View

Stancil S, Miller M, Briggs H, Lynch D, Goggin K, Kearns G . Contraceptive Provision to Adolescent Females Prescribed Teratogenic Medications. Pediatrics. 2015; 137(1). DOI: 10.1542/peds.2015-1454. View

Schwarz E, Santucci A, Borrero S, Akers A, Nikolajski C, Gold M . Perspectives of primary care clinicians on teratogenic risk counseling. Birth Defects Res A Clin Mol Teratol. 2009; 85(10):858-63. PMC: 2805273. DOI: 10.1002/bdra.20599. View

Kazmerski T, Nelson E, Newman L, Haviland M, Luff D, Leichtner A . Interprofessional provider educational needs and preferences regarding the provision of sexual and reproductive health care in cystic fibrosis. J Cyst Fibros. 2019; 18(5):671-676. DOI: 10.1016/j.jcf.2019.01.015. View

Lesage N, Deneux Tharaux C, Saucedo M, Habibi A, Galacteros F, Girot R . Maternal mortality among women with sickle-cell disease in France, 1996-2009. Eur J Obstet Gynecol Reprod Biol. 2015; 194:183-8. DOI: 10.1016/j.ejogrb.2015.09.016. View

Eissa A, Tuck S, Rantell K, Stott D . Trends in family planning and counselling for women with sickle cell disease in the UK over two decades. J Fam Plann Reprod Health Care. 2014; 41(2):96-101. DOI: 10.1136/jfprhc-2013-100763. View

Hershberger P, Gallo A, Molokie R, Thompson A, Suarez M, Yao Y . Toward understanding family-related characteristics of young adults with sickle-cell disease or sickle-cell trait in the USA. J Clin Nurs. 2016; 25(11-12):1587-97. PMC: 4854774. DOI: 10.1111/jocn.13144. View

10.

OBrien S, Klima J, Reed S, Chisolm D, Schwarz E, Kelleher K . Hormonal contraception use and pregnancy in adolescents with sickle cell disease: analysis of Michigan Medicaid claims. Contraception. 2011; 83(2):134-7. DOI: 10.1016/j.contraception.2010.06.017. View

11.

Espinera A, Gavvala J, Bellinski I, Kennedy J, Macken M, Narechania A . Counseling by epileptologists affects contraceptive choices of women with epilepsy. Epilepsy Behav. 2016; 65:1-6. DOI: 10.1016/j.yebeh.2016.08.021. View

12.

Pecker L, Hussain S, Lanzkron S, Tao X, Thaler K, Burke A . Women with sickle cell disease report low knowledge and use of long acting reversible contraception. J Natl Med Assoc. 2021; 113(5):552-559. PMC: 10206766. DOI: 10.1016/j.jnma.2021.05.005. View

13.

Oteng-Ntim E, Pavord S, Howard R, Robinson S, Oakley L, Mackillop L . Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline. Br J Haematol. 2021; 194(6):980-995. DOI: 10.1111/bjh.17671. View

14.

Halsey C, Roberts I . The role of hydroxyurea in sickle cell disease. Br J Haematol. 2003; 120(2):177-86. DOI: 10.1046/j.1365-2141.2003.03849.x. View

15.

Nahata L, Caltabellotta N, Ball K, OBrien S, Creary S . Desire for parenthood and reproductive health knowledge in adolescents and young adults with sickle cell disease and their caregivers. Pediatr Blood Cancer. 2017; 65(2). DOI: 10.1002/pbc.26829. View

16.

Bhakta J, Bainbridge J, Borgelt L . Teratogenic medications and concurrent contraceptive use in women of childbearing ability with epilepsy. Epilepsy Behav. 2015; 52(Pt A):212-7. DOI: 10.1016/j.yebeh.2015.08.004. View

17.

Pecker L, Lanzkron S . Sickle Cell Disease. Ann Intern Med. 2021; 174(1):ITC1-ITC16. DOI: 10.7326/AITC202101190. View

18.

Piel F, Steinberg M, Rees D . Sickle Cell Disease. N Engl J Med. 2017; 377(3):305. DOI: 10.1056/NEJMc1706325. View

19.

De Sanctis V, Soliman A, Daar S, Canatan D, Di Maio S, Kattamis C . Current Issues and Options for Hormonal Contraception in Adolescents and Young Adult Women With Sickle Cell Disease: An Update for Health Care Professionals. Mediterr J Hematol Infect Dis. 2020; 12(1):e2020032. PMC: 7202337. DOI: 10.4084/MJHID.2020.032. View

20.

Boafor T, Olayemi E, Galadanci N, Hayfron-Benjamin C, Dei-Adomakoh Y, Segbefia C . Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis. BJOG. 2015; 123(5):691-8. DOI: 10.1111/1471-0528.13786. View